Autopsy report · NCT01814865

Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer

“Funding was not acquired”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

British Columbia Cancer Agency

Sponsor type

University, hospital or other

Conditions

Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer

Interventions

Abiraterone Acetate; Prednisone; Aromatase Inhibitor

Participants

0

Sites

4

Countries

Canada

Trials that died the same way

• 4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine
  “Funding not acquired” (96% match in meaning)
• Brain Sleep Deprivation MRI Effects (BEDTIME)
  “Funding was not obtained” (92% match in meaning)
• Effects of Steroid Tapering on Functional Capacity and Neurocognition
  “Funding not obtained” (87% match in meaning)
• A Breathing-Based Meditation Intervention for Patients With Treatment Resistant Late Life Depression
  “Funding was not received.” (84% match in meaning)
• Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
  “Funding was not available” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.